By placing an order the buyer agrees to Zedira's General Trade Conditions (GTC).


Invoice Address


(Information about new products, special offers and new developments in celiac disease and blood coagulation, about 8 editions annually.)


Shipping Address (when different)


(Information about new products, special offers and new developments in celiac disease and blood coagulation, about 8 editions annually.)


Payment


(3 figure number)


Shipping




How did you find out about our products and us?






Print the order sheet and send it via Fax or send the file attached to an e-mail.

By placing an order the buyer agrees to Zedira's General Trade Conditions (GTC).

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.
    All products

News  

  • imageSuccessful ISO9001:2015 recertification
    Read more All news
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
    Read more All news
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
    Read more All news
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
    Read more All news
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
    Read more All news
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
    Read more All news
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
    Read more All news

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
    Read more All posts
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
    Read more All posts
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering
    Read more All posts

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy

    All events